1. Home
  2. BGT vs IFRX Comparison

BGT vs IFRX Comparison

Compare BGT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Floating Rate Income Trust

BGT

BlackRock Floating Rate Income Trust

SELL

Current Price

$10.11

Market Cap

318.8M

Sector

Finance

ML Signal

SELL

Logo InflaRx N.V.

IFRX

InflaRx N.V.

BUY

Current Price

$1.45

Market Cap

303.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
BGT
IFRX
Founded
N/A
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
318.8M
303.4M
IPO Year
2004
2017

Fundamental Metrics

Financial Performance
Metric
BGT
IFRX
Price
$10.11
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $7.68
AVG Volume (30 Days)
156.6K
★ 548.7K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.92
$0.80
52 Week High
$11.95
$2.95

Technical Indicators

Market Signals
Indicator
BGT
IFRX
Relative Strength Index (RSI) 28.15 31.12
Support Level N/A $0.81
Resistance Level $10.87 $2.94
Average True Range (ATR) 0.15 0.11
MACD -0.02 -0.02
Stochastic Oscillator 19.38 22.31

Price Performance

Historical Comparison
BGT
IFRX

About BGT BlackRock Floating Rate Income Trust

Blackrock Floating Rate Income Trust is a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The company, as a secondary objective, also focuses on preservation of capital to the extent consistent with its primary objective of high current income. The Trust seeks to achieve its investment objectives by investing in worl-wide portfolio of floating rate securities, including investing a substantial amount in U.S. and non-U.S. senior secured floating rate loans (Senior Loans), made to corporate and other business entities.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: